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Abstract
Background: Fever in neutropenia (FN) remains a frequent complication in pedi-
atric patients undergoing chemotherapy for cancer. Preventive strategies, like primary
antibiotic prophylaxis, need to be evidence-based.
Procedure:Data on pediatric patients with any malignancy from the prospective mul-
ticenter SPOG 2015 FN Definition Study (NCT02324231) were analyzed. A score
predicting the risk to develop FN with safety-relevant events (SRE; bacteremia,
severe sepsis, intensive care unit admission, death) was developed using multivariate
mixed Poisson regression. Its predictive performance was assessed by internal cross-
validation and comparedwith the performance of published rules.
Results: In 238 patients, 318 FN episodes were recorded, including 53 (17%) with
bacteremia and 68 (21%) with SRE. The risk-prediction score used three variables:
chemotherapy intensity, defined according to the expected duration of severe neu-
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acutemyeloid leukemia; AUC, area under the curve; CNS, central nervous system; CVAD, central venous access device; FN, fever in
neutropenia; HSCT, hematopoietic stem cell transplantation; IC, informed consent; NHL, non-Hodgkin lymphoma; PT, proportion of time; SMC, serious medical complication; SPOG, Swiss
Paediatric Oncology Group; SRE, safety-relevant event; TNC, time needed to cover; TNP, time needed to prevent.
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tropenia, time sincediagnosis, and typeofmalignancy. Its cross-validatedperformance,
assessed by the time needed to cover (TNC) one event, exceeded the performance of
published rules. A clinically useful score threshold of ≥11 resulted in 2.3% time at risk
and 4.1months TNC. Using external information on efficacy and timing of intermittent
antibiotic prophylaxis, 4.3 months of prophylaxis were needed to prevent one FNwith
bacteremia, and 5.2months to prevent one FNwith SRE, using a threshold of≥11.
Conclusions:This score, basedon three routinely accessible characteristics, accurately
identifies pediatric patients at risk to develop FN with SRE during chemotherapy. The
score can help to design clinical decision rules on targeted primary antibiotic prophy-
laxis and corresponding efficacy studies.
KEYWORDS
antibiotic prophylaxis, febrile neutropenia, infections in immunocompromisedhosts, neutropenia,
pediatric oncology, risk-prediction score
1 INTRODUCTION
Chemotherapy-induced neutropenia is a major risk factor for severe
infections in patients with cancer.1 Despite improved medical man-
agement, fever in neutropenia (FN) continues to be associated with
significant morbidity and mortality.2 Preventive strategies, like pri-
mary antibiotic prophylaxis, potentially reduce morbidity and mortal-
ity, but must be evidence- and risk-based. The efficacy of antibiotic
prophylaxis, measured by the reduction of mortality and of FN with
complications, must be weighted prudently against potential adverse
events.3
A current systematic review of randomized controlled trials on
the efficacy of antibiotic prophylaxis in adult and pediatric patients
with cancer and recipients of hematopoietic stem cell transplantation
(HSCT) found antibiotic prophylaxis to significantly reducebacteremia,
but not overall mortality.4
In pediatric oncology, current clinical guidelines present conflicting
and only weak recommendations for5 and against6 antibiotic prophy-
laxis during chemotherapy for selected patient groups. These discrep-
ancies are explained by different methodologies in guideline develop-
ment, but mainly reflect the paucity of clinical evidence on the efficacy
of primary antibiotic prophylaxis beyond Pneumocystis jirovecii pneu-
monia prophylaxis.
Studieswith a priori-defined, diagnosis-based risk groups only allow
restricted conclusions. Power calculation for future studies remains
difficult because of insufficient data on the potential efficacy of
prophylaxis.7 For targeted primary antibiotic prophylaxis, better pre-
diction of the risk to develop bacterial infections with complications
during chemotherapy is needed.3
This analysis of data frompediatric patients undergoing chemother-
apy for cancer aimed to analyze associations of clinical characteris-
tics with the risk to develop FN with safety-relevant events (SRE;
bacteremia, severe sepsis, intensive care admission, death) during
chemotherapy; to derive a risk-prediction score for FNwith SREduring
chemotherapy; to estimate the score’s performance including effect
size; and to evaluate its performance compared with published scores
or clinical decision rules.
2 METHODS
2.1 Study design
The prospective multicenter Swiss Paediatric Oncology Group (SPOG)
2015FNDefinition Studywas opened for recruitment in six out of nine
pediatric oncology centers in Switzerland from April 2016 to August
2018. Patients, if able to judge, and their legal guardians gave written
informed consent (IC) before study entry. The study was conducted in
accordance with the Declaration of Helsinki and the Swiss law, which
refers to the current Good Clinical Practice guidelines. It had been reg-
istered atClinicalTrials.gov (NCT02324231) andwas approvedby local
ethics committees before patient recruitment.8 Data were collected
andmanaged using REDCap electronic data capture tools.9
The SPOG 2015 FN Definition Study was designed to determine
the safety of a higher (39.0◦C) versus lower (38.5◦C) fever limit using
a nonblinded cluster-randomized controlled non-inferiority design.
Patients, clustered via centers, weremonthly randomized to one of the
two fever limits. The 39.0◦C fever limit has been found to be both safe
and efficacious when compared to 38.5◦C; details have been published
elsewhere.8 In this manuscript, an analysis of observational outcomes
predefined in the protocol10 is reported.
2.2 Patients and management of FN
Patients treated with chemotherapy for cancer were consecutively
screened. Inclusion criteria were age ≥12months and<18 years, diag-
nosis of anymalignancy, treatment withmyelosuppressive chemother-
apy expected to last ≥2 months, or greater than or equal to one cycle
of myeloablative chemotherapy, followed by autologous HSCT, and
written IC. Patients after allogeneic HSCT were excluded.8 After IC,
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patients were studied during the course of their chemotherapy. Infor-
mation on clinical characteristics and FN, including the outcomes ana-
lyzed here, was collected eachmonth.
Neutropenia was defined as an absolute neutrophil count<0.5 G/L,
or <1.0 G/L and expected to decline to <0.5 G/L within 48 hours.11,12
Temperature was measured in the ear by infrared tympanic thermom-
etry. FN was diagnosed in outpatients and inpatients when temper-
ature reached the randomized fever limit (38.5◦C or 39.0◦C), but
diagnosis below this limit was allowed if clinically indicated. Diag-
nosis of FN implied emergency hospitalization, essential laboratory
tests, and start of empirical intravenous broad-spectrum antimicro-
bial therapy. Coverage of Gram-positive cocci and Gram-negative
bacteria was required, but a specific antianaerobic coverage was
not.10 Each center chose antibiotics according to local resistance
patterns.8
In order to avoid a systematic bias, all patients from centers rou-
tinely applying primary antibiotic prophylaxis, beyond prophylaxis of
Pneumocystis jirovecii pneumonia, in predefined patient groups were
excluded from this analysis.
2.3 Outcomes
Restarting antibiotics within 7 days and with persistent neutropenia
was considered to belong to the same FN episode, as long as intra-
venous chemotherapy had not been restarted. Correspondingly, all
outcomes were trackedwithin this 7-day period.8
The four main outcomes were FN, FN with bacteremia, with a
serious medical complication (SMC), or with an SRE. Bacteremia was
defined by detection of a recognized pathogen from one ormore blood
cultures according to current definitions.11,13 An SMC was defined
as death due to any cause during FN, admission to an intensive care
unit, high dependency unit or other critical care unit for organ sup-
port, or severe sepsis (including septic shock) according to established
definitions.14 SRE was defined as bacteremia or SMC. Infections other
than bacteremia were thus included in the SRE definition if they led to
an SMC.
2.4 Statistical analysis
Associations of the following 11 clinical characteristics with the four
main outcomes were analyzed: sex, age group at screening, type of
malignancy, relapse status, bone marrow involvement, chemotherapy
intensity, presence of any central venous access device (CVAD), time
since diagnosis, prior episodes of FN, prior episodes of FN with bac-
teremia, and season of FN.
Chemotherapy intensity was split into four categories, defined
according to the expected duration of severe neutropenia.15,16 Time
sincediagnosiswas split into three categories, resulting fromcollapsing
13 initial categories by the adjacent categoriesmethod, applying three-
level mixed Poisson regression on FN with SRE.17,18 In Switzerland,
viral infections aremuchmore commonduring autumnandwinter. Sea-
son was therefore split into two predefined categories, spring/summer
(March to August) and autumn/winter (September to February). Port-
a-caths were the most common reported CVAD systems, used in 160
(98%)of 164years of cumulative chemotherapy time. Thereforeno fur-
ther splitting of CVADwas done for analysis.
Analysis included univariate and multivariate three-level mixed
Poisson regression analysis with chemotherapy time as rate multi-
plier. Random intercepts per patient, nested within center, were used
to account for multiple randomization periods and FN episodes per
patient. Interaction terms of clinical characteristics with the random-
ized fever limitwerenonsignificant in all univariate analyses. Thus, con-
founding of the risk prediction analyses presented here by the random-
ized study design could be excluded.
Characteristics significantly associated in univariate analyses were
used for the construction ofmultivariatemixedPoisson risk-prediction
models (stepwise procedure, p< .05 for entry and for removal).19
A risk-prediction score was derived from the multivariate mixed
Poisson model for FN with SRE. Its weights equaled the model coef-
ficients multiplied by 2 and then rounded to the nearest integer. The
score was the sum of these weights.
The predictive performance of this score was assessed by twomea-
sures. First, the area under the curve (AUC) of sensitivity versus time
declared to be at risk was calculated as a global performance measure.
Second, the time needed to cover (TNC) one event was calculated for
all potential thresholds of the score, by dividing the time at risk by
the number of events observed during this time. Time at risk was the
cumulative chemotherapy time at or above a specific score threshold.
Comparable to the number needed to treat (NNT) as an efficacy mea-
sure for treatments, the TNC is a measure for the potential efficacy of
primary antibiotic prophylaxis. The TNC is directly linked to the time
needed to prevent (TNP) one event with continuous antibiotic prophy-
laxis by the equation TNPc = TNC/efficacy of prophylaxis. With per-
fect efficacy, TNPc equals TNC, but with nonperfect prophylaxis, TNPc
exceeds TNC. Clinically, antibiotic prophylaxis is usually applied inter-
mittently by, for example, delayed starting and stopping after resolu-
tion of severe neutropenia.7 The resulting clinically meaningful TNPi
is the time needed to prevent one event by intermittent prophylaxis.
Defined by TNPi = TNPc*PTi, it is shorter than TNPc, because PTi, the
proportion of time with intermittent prophylaxis, is below 1 by defi-
nition. Taken together, TNPi depends on the TNC described here, the
efficacy of prophylaxis, and the proportion of time with intermittent
prophylaxis as follows: TNPi = (TNC/efficacy)*PTi. To calculate TNPi,
external information on efficacy and timing of intermittent antibiotic
prophylaxiswere extracted froma recently published randomized con-
trolled trial.7
Multiple random replications of 10-fold internal patient-level cross-
validation were used for three aims. First, 100 replications per model
aimed to detect overfitting, defined by decreasing median AUC in suc-
cessive steps, in stepwise multivariate model generation. Second, 100
replications per score aimed to confirm that increasing score complex-
ity led to significantly increased score performance assessed by AUC.
Third, 1000 replications of the final score aimed to give robust esti-
mates of the score’s TNCs at different thresholds.
The predictive performance of the risk-prediction score developed
here was compared with the performance of published scores or
clinical decision rules. Specifically, TNCs of the score in these 1000
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replications were compared with TNCs of published rules in 1000
patient-level bootstrapping replications of the dataset at comparable
(ratio 0.9–1.1) proportions of time at risk.
Tests were two-sided throughout, p-values < .05 were considered
significant and correspondingly, 95% confidence intervals were calcu-
lated. All analyses were performed using R 3.6.3.20 Specifically, the
“glmer” function from the “lme4” library21 was used for mixed Poisson
regression, the “glmmPQL” function from the “MASS” library22 when
“glmer” failed, and the “pROC” library23 for AUC calculation.
3 RESULTS
3.1 Centers, patients, and FN episodes
In one of the six participating SPOG centers recruiting patients
for this study, systematic primary antibiotic prophylaxis was given
to patients with acute myeloid leukemia (AML) and with high-risk
or relapsed acute lymphoblastic leukemia (ALL). Results of the 238
patients recruited in the remaining five centers are analyzed here.
Their median age at screening was 7 years (interquartile range, 4–
12), and 97 (41%) were female. Characteristics did not differ between
patients studied and patients without IC on file, except for recruitment
differences between centers (Table S1).
During 173 years (63,122 days) of cumulative chemotherapy time,
318 FN episodeswere recorded, 53 (17%) of themwith bacteremia, 28
(9%)with SMC, and68 (21%)with at least oneSRE (Table S2, Figure S1).
3.2 Associations of clinical characteristics with
FN episodes
Nine of the 11 clinical characteristics studied were significantly asso-
ciated with the risk to develop FN during chemotherapy in univari-
ate analysis. Five of these characteristics remained significantly and
independently associated with the risk to develop FN in multivari-
ate analysis. These were chemotherapy intensity, time since diagnosis,
prior episodes of FN, season and type of malignancy. Internal cross-
validation detected overfitting by inclusion of the last two character-
istics (Tables S3 and S4).
Five clinical characteristics were significantly associated with FN
with bacteremia in univariate analysis. Three remained significantly
and independently associated with FN with bacteremia in multivari-
ate analysis. These were chemotherapy intensity, time since diagnosis,
and type of malignancy. Internal cross-validation detected overfitting
by inclusion of the last characteristic (Tables S3 and S4).
Three clinical characteristics were significantly associated with FN
with SMC in univariate analysis. Two remained significantly and inde-
pendently associatedwith FNwith SMC inmultivariate analysis. These
were chemotherapy intensity and type of malignancy. Internal cross-
validation detected no overfitting (Tables S3 and S4).
Six clinical characteristics were significantly associated with FN
with SRE in univariate analysis (Table 1). Three remained significantly
and independently associated with FN with SRE in multivariate analy-
sis. These were, like for FN with bacteremia, chemotherapy intensity,
time since diagnosis, and type of malignancy (Table 2). Internal cross-
validation detected no overfitting.
3.3 Scoring system to predict FN episodes with
SRE
The score predicting the risk to develop FN with SRE during
chemotherapy was based on the multivariate model. Risk prediction,
assessed by AUC, improved significantly in scores based on one ver-
sus two versus three variables (median of 100 cross-validations, 0.745
versus 0.768 versus 0.777; p < .001 for both comparisons). The final
risk-prediction scorewas thus based on three variables, chemotherapy
intensity, time since diagnosis, and type of malignancy (Table 2). It had
15 levels, ranging from 0 to 14 (Figure 1, Table 3; Table S5 and S6). The
noncross-validated AUC of this SRE-based score was 0.753 for predic-
tion of FN as such, 0.840 for FN with bacteremia, 0.798 for FN with
SMC, and 0.823 for FNwith SRE.
3.4 Performance of the score
As expected, median cross-validated TNCs were slightly higher than
noncross-validated TNCs for prediction of FNwith SRE, bacteremia or
SMC, and of FN as such (Figure 1; Figure S2, Table S7). For prediction
of FN with SRE, two clinically useful score thresholds were found by
graphical TNC analysis (Figure 1).
Applying the first threshold of scores ≥11, including 2.3%
chemotherapy time at risk, the TNC was 3.2 months per FN with
SRE (median of cross-validations 4.1; Table 4). Clinically, this threshold
included intensive chemotherapy cycles for patients with AML and
mature B-cell non-Hodgkin lymphoma (NHL), and myeloablative ther-
apy before autologous HSCT for patients with NHL and solid tumors
outside the central nervous system (CNS), all during the first 7 months
of chemotherapy (Table 3; Table S5 and S6).
Applying the second threshold of scores ≥8, including 24.9%
chemotherapy time at risk, the TNC was 9.9 (median of cross-
validations12.1; Table4). Clinically, this threshold additionally included
intensive chemotherapy cycles for patients with ALL within the first
7 months of chemotherapy, and myeloablative therapy before autol-
ogous HSCT for patients with Hodgkin lymphoma, NHL, CNS tumors,
and solid tumors outside the CNS irrespective of timing. These two
thresholds were confirmed for prediction of FN with bacteremia, with
SMC, and for FN as such (Figure S3, Table S7).
3.5 External validation and performance of
published models, scores, and rules
A PubMed search for published risk-prediction models, scores,
and rules up to February 9, 2021 using search terms for “fever,”
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TABLE 1 Associations of clinical characteristics with FNwith SRE, univariate analysis
FNwith SRE




Male 96 41 Reference
Female 77 27 0.75 (0.38–1.47) .40
Age at screening (years)
1–4 54 30 Reference –
5–8 52 16 0.57 (0.31–1.04) .067
9–12 29 6 0.38 (0.16–0.92) .032
≥13 37 16 0.75 (0.41–1.38) .35
Disease-related characteristics
Type of malignancy
Acute lymphoblastic leukemia 105 41 Reference –
Acutemyeloid leukemia 4 10 7.45 (2.81–19.8) <.001
Hodgkin lymphoma 7 1 0.35 (0.05–2.70) .32
Non-Hodgkin lymphoma 10 6 1.67 (0.61–4.56) .32
Central nervous system tumor 17 2 0.29 (0.07–1.28) .10
Other solid tumor 31 8 0.67 (0.30–1.51) .33
Relapse status
No relapse 159 63 Reference
Relapsedmalignancy 13 5 1.36 (0.42–4.39) .61
Bonemarrow involvement
None 168 58 Reference –
Bonemarrow involvement 5 10 4.97 (2.36–10.5) <.001
Characteristics of therapy and course
Chemotherapy intensity (expected neutropenia)
1 (none) 80 5 Reference –
2 (≤10 days) 88 46 8.73 (3.43–22.2) <.001
3 (>10 days) 3 14 72.9 (23.7–224) <.001
4 (myeloablative) 1 3 29.3 (6.45–133) <.001
Central venous access device
None 9 0 Reference –
Any type implanted 164 68 Model failure –
Time since diagnosis
<1month 9 12 14.2 (5.80–35.0) <.001
1 to<8months 74 47 6.30 (3.01–13.2) <.001
≥8months 90 9 Reference –
Prior episode of FN
No 89 31 Reference –
Yes 84 37 0.75 (0.41–1.38) .36
Prior episode of FNwith bacteremiaa
No 142 52 Reference –
Yes 31 16 1.29 (0.68–2.45) .43
(Continues)
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TABLE 1 (Continued)
FNwith SRE
Characteristics CT Events Rate ratio (95%CI) p-Value
Season
Spring/Summer 99 30 Reference –
Autumn/Winter 74 38 1.86 (1.13–3.06) .015
Note: Displayed are results of univariate three-level mixed Poisson regression.
Abbreviations: CI, confidence interval; CT, chemotherapy time in years; FN, fever in neutropenia; SRE, safety-relevant event.
aResults of glmmPQL function because of model failure using the glmer function.
“neutropenia,” and “children,” including forward citation searching,
gave two results. Wicki et al. reported in 2008 on a retrospective
single-center study.24 Higher chemotherapy intensity, shorter time
since diagnosis, prior episodes of FN, bone marrow involvement, and
presence of a CVAD were significantly associated with the risk to
develop FN and FNwith bacteremia. Applied on the dataset described
here, the Wicki multivariate model resulted in 260 levels. For 6 of 7
score thresholds ≥8, comparisons of TNCs with corresponding Wicki
thresholds were possible. The cross-validated TNCs for SRE of the
score developed here were always comparable (within 1 day; thresh-
olds 8, 9, 10, 14) or significantly lower (thresholds 12, 13) than the cor-
respondingmedian bootstrappedTNCofWicki et al. (Figure 1, Table 4).
A guideline published by Lehrnbecher et al. in 2020 recommends
antibacterial prophylaxis for pediatric patients with AML and relapsed
ALL during intensive chemotherapy.5 At the corresponding thresh-
old ≥11 (time at risk, 2.3% vs. 3.1%), the median cross-validated
TNC for SRE of the score developed here was significantly lower
than the median bootstrapped Lehrnbecher TNC (p < .001; Table 4,
Figure 1).
Using external information on efficacy and timing of intermittent
prophylaxis froma recently published randomized controlled trial,7 the
TNPi was 4.3 months per FN with bacteremia and 5.2 months per FN
with SRE using a threshold of≥11 (Table 5).
4 DISCUSSION
This analysis developed a score predicting the risk for FN with SRE in
pediatric patients treated with chemotherapy for cancer. At least one
SRE was reported in 21% of FN episodes. The score developed here
was based on three easily accessible clinical characteristics, intensity
of chemotherapy, time since diagnosis, and type of malignancy.
The overall performance of this score to predict FN with SRE was
good, the median cross-validated AUC of sensitivity versus proportion
of time at risk was 0.777 (noncross-validated 0.823).
However, the predictive performance in high-risk situations is more
important than the overall performance for targeted primary antibiotic
prophylaxis. The TNC introduced here is a quantitative measure of the
maximum effect size of such primary prophylaxis. It can help to weigh
potential benefits versus adverse events and further drawbacks of pro-
phylaxis. A restrictive score threshold of≥11 resulted in 2.3%high-risk
time,with a cross-validated TNCone FNwith SRE of 4.1months, which
corresponds to 5.2 months of intermittent prophylaxis to prevent one
FNwith SRE (TNPi).
The score and its TNC/TNPi results can be mainly used for three
purposes. First, if the prevention of one FN episode with SRE is consid-
ered to outweigh thedrawbacks of, for example, half a year of antibiotic
prophylaxis, a threshold of ≥11 can directly serve as a clinical decision
rule to define patient groups for targeted primary antibiotic prophy-
laxis. Second, for patient groups with intermediate TNCi, for example,
from 6 to 12 months, the results can inform power analysis and fur-
ther design questions of future efficacy studies of antibiotic prophy-
laxis. Third, efficacy studies should be avoided in patient groups with
TNPi above a clinically meaningful limit of,for example, 12months.
Four randomized, placebo-controlled studies have analyzed the effi-
cacy of antibacterial prophylaxis in children undergoing chemotherapy
for hematologic malignancies or solid tumors.725–27 Results ranged
from no effect25 to an efficacy of 0.3126 for the reduction of FN.
Only one study, investigating the effect of levofloxacin, had enough
power to investigate efficacy of prophylaxis in reducing FN with bac-
teremia (0.48) and severe infections (0.38).7 Meta-analyses in adult
and pediatric patients had found prophylaxis with fluoroquinolones to
be efficacious in certain patient groups, but report inconsistent data on
resistance.28 A future UK studywill compare ciprofloxacin prophylaxis
versus standard of care during induction therapy in pediatric patients
with ALL treated in the ALLTogether-1 study.29
For the prediction of FN with SRE, the score developed here sig-
nificantly outperformed a more complex published prediction model
basedon five variables24 anda recent clinical decision ruleonantibiotic
prophylaxis.5 TheFENCE score,30 developed in adult patients to assess
the FN risk during the first cycle of chemotherapy, confirmed the rele-
vance of two of the three score components, type of malignancy and
chemotherapy intensity, irrespective of patient age.
A limitation of this analysis is that information on other comorbidi-
ties and biochemical markers that might influence the risks analyzed
was not available. A second limitation is the small number of patients
treated with intensive chemotherapy, such as AML-type and myeloab-
lative regimens.8 Before clinical application in these patients, this score
should be validated prospectively. A third limitation is that the centers
used different antibiotics for treatment of FN. Validation studies have
to show, how this impacts the generalizability of the results. A fourth
limitation is the single-country setting of the study, Switzerland being
a high-income country. These results are thus only valid for countries
with comparable settings.
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F IGURE 1 Frequencies of risk-prediction scores in the FN
episodes studied here, plus the corresponding TNCs. The histogram,
displayed in grey, shows the frequency distribution of the
risk-prediction score developed here (SPOG 2015 FNDefinition
score; y-axis on the right). The remaining information is on the
corresponding time needed to cover (TNC) using different score
thresholds (y-axis on the left). Specifically, open circles joined by a
solid black line indicate the noncross-validated TNCs of the score. The
boxplots showmedian and interquartile range (IQR) of cross-validated
TNCs (blue), of bootstrapped TNCs for corresponding thresholds from
Wicki et al. (green), and from Lehrnbecher et al. (red)
Major strengths of this analysis are its large base of prospectively
collected data in a multicenter study setting with nonbiased recruit-
ment of patientswith awide and representative spectrumofmalignan-
cies. Internal cross-validation avoided overfitting of the multivariate
model and, thus, the score. Nonsignificant results of interaction anal-
yses excluded relevant confounding of the score by the randomized
design of the underlying trial. The score developed here is easy to cal-
culate based on three routinely accessible patient characteristics and
is applicable during the entire chemotherapy.
In conclusion, the score developed here, based on three routinely
accessible characteristics, accurately identifies pediatric patients with
cancer at risk to develop FNwith SRE during chemotherapy. The score,
together with the effect size measures presented, can help to design
clinical decision rules on targeted primary antibiotic prophylaxis and
corresponding efficacy studies.
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TABLE 3 Scores of common clinical situations, sorted according to scores, 7–14
Score Malignancy and therapy Chemotherapy intensity
Time since
diagnosis(months)
14= 3+ 8+ 3 AML intensive 3 <1
13= 3+ 8+ 2 AML intensive 3 1 to<8
13= 2+ 8+ 3 Mature B-NHL 3 <1
13= 3+ 8+ 2 AML intensive 3 1 to<8
13= 2+ 8+ 3 Mature B-NHL 3 <1
12= 2+ 8+ 2 Mature B-NHL 3 1 to<8
12= 2+ 8+ 2 NHL auto HSCT 4 1 to<8
12= 2+ 8+ 2 Solid auto HSCT 4 1 to<8
10= 4+ 3+ 3 ALL intensive 2 <1
10= 0+ 8+ 2 HL auto HSCT 4 1 to<8
10= 2+ 8+ 0 NHL auto HSCT 4 ≥8
10= 0+ 8+ 2 CNS auto HSCT 4 1 to<8
10= 2+ 8+ 0 Solid auto HSCT 4 ≥8
9= 4+ 3+ 2 ALL intensive 2 1 to<8
8= 0+ 8+ 0 HL auto HSCT 4 ≥8
8= 2+ 3+ 3 NHL intensive 2 <1
8= 0+ 8+ 0 CNS auto HSCT 4 ≥8
8= 2+ 3+ 3 Solid intensive 2 <1
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acutemyeloid leukemia; auto, autologous; B-NHL, B-cell non-Hodgkin lymphoma; CNS, central ner-
vous system; HL, Hodgkin lymphoma; HSCT, hematopoietic stem cell transplantation; NHL, non-Hodgkin lymphoma.
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